Interleukin-33, endothelin-1, and inflammatory parameters in chronic spontaneous urticaria

What Was Tested

The paper reports a study of Endothelin-1, published as a observational study.

Background: Endothelin-1 (ET-1) and interleukin-33 (IL-33) can modulate the activation of mast cells and basophils in the pathophysiology of allergic diseases, interplaying with other mediators of "low-grade inflammation." Objective: To compare ET-1, IL-33, the neutrophil-lymphocyte ratio (NLR), eosinophil-lymphocyte ratio (ELR), platelet-lymphocyte ratio (PLR), eosinophil-basophil ratio (EBR), systemic immune inflammation index (SII), and system inflammation response index (SIRI) in patients with chronic spontaneous urticaria (CSU) and are antihistamine sensitive (AHS), antihistamine resistant (AHR), omalizumab sensitive (OmS), and omalizumab resistant (OmR).

Why It Was Studied

Methods: A prospective observational study enrolled 68 consecutive patients with CSU diagnosed and managed according to the dermatology section of the European Academy of Allergology and Clinical Immunology (EAACI), the European Union funded network of excellence, the Global Allergy and Asthma European Network (GA2LEN), the European Dermatology Forum (EDF), and the World Allergy Organization guidelines.

Patients with a urticaria control test score of >12 are considered treatment sensitive, and ≤ 12 are considered resistant.

Who Took Part

The study group was 68 patients.

Results: Thirty AHS group, 38 AHR group, and 20 control group patients were included.

How the Study Was Run

Total immunoglobulin E (IgE), antinuclear antibodies (ANA), thyroid stimulating hormone, antithyroid peroxidase, mean platelet volume (MPV), NLR, ELR, PLR, EBR, SII, SIRI, ET-1, and IL-33 were measured at the study entry and compared between the study groups.

What Was Measured

Patients with a urticaria control test score of >12 are considered treatment sensitive, and ≤ 12 are considered resistant.

Topics PubMed links to this paper include Omalizumab, Anti-Allergic Agents, Interleukin-33, Endothelin-1, C-Reactive Protein, Chronic Urticaria and Urticaria.

What This Means in Plain Language

This is a observational study of Endothelin-1 in 68 patients.

The publication is from 2023 (Allergy and asthma proceedings), a journal based in United States.

More context: the Endothelin-1 compound page, all human trials.